CMS to exclusively distribute two Vifor products in China


Vifor Pharma has entered into an exclusive distribution agreement with China Medical System Holdings (CMS) for the former's products, Uro-Vaxom and Maltofer. Under the agreement, CMS will have rights to distribute the products in the People's Republic of China, excluding Hong Kong, Macao and Taiwan. CMS will also assume responsibility for registering the products in China. The agreement is for ten years from the date of the first commercialisation of the products in China, and will be automatically extended for a further five years if certain sales targets are met.

Uro-Vaxom is an extract Escherichia coli for the treatment and prevention of recurrent urinary tract infections that stimulates the immune system and the body's natural defence against urinary pathogens. Maltofer is an oral iron supplement developed by Vifor for the treatment of iron deficiency without anaemia and iron deficiency anaemia, which has been marketed globally in more than 80 countries.



Agreement Information:
Agreement Status: New Date Announced: 17 Jan 2012
Date Last Reported: Duration: 10 years
Est Total Value: Investment To Date:
Agreement Type: Commercialisation
Generic / Brand Name:
Therapeutic Area: Blood and Blood Forming Organs Genito-urinary System and Sex Hormones
Indication: Anaemia Bacterial infections (urinary tract)
Techonology/Field: N/A



Agreement Information:
Agreement Status: New Date Announced: 17 Jan 2012
Date Last Reported: Duration: 10 years
Est Total Value: Investment To Date:
Agreement Type: Commercialisation
Generic / Brand Name:
Therapeutic Area: Blood and Blood Forming Organs Genito-urinary System and Sex Hormones
Indication: Anaemia Bacterial infections (urinary tract)
Techonology/Field: N/A
This article is tagged to:
Sector: Pharmaceuticals & Healthcare
Geography: Switzerland, China, Switzerland, Hong Kong, Taiwan, Taiwan, China, China

Related products in our Store...

Check out our most popular reports below or view more in our store